Open AccessPS1387 CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS FROM PHASE 3 ASPIRE AND ENDEAVOR
Author(s) -
Facon T.,
Niesvizky R.,
Weisel K.,
Bringhen S.,
Ho P.J.,
Obreja M.,
Yang Z.,
Klippel Z.,
Blaedel J.,
Mezzi K.,
Siegel D.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000563824.64379.80
Subject(s) - carfilzomib , medicine , lenalidomide , multiple myeloma , dexamethasone , oncology , refractory (planetary science) , charlson comorbidity index , comorbidity , physics , astrobiology
Background: Carfilzomib (K)‐based regimens improved progression‐free survival (PFS) and overall survival (OS) in relapsed and refractory multiple myeloma (RRMM) patients (pts) in ASPIRE (K [27 mg/m2]‐lenalidomide‐dexamethasone [KRd] vs Rd) and ENDEAVOR (K [56 mg/m2]‐dexamethasone [Kd56] vs bortezomib‐dexamethasone [Vd]), regardless of age. Frailty scores have been developed based on age, comorbidities, and functional status (Palumbo Blood 2015;125:2068–74; Facon Blood 2015;126:4239). Aims: We assessed post‐hoc pt outcomes by frailty status. Methods: PFS, OS, and safety were assessed by treatment arm and frailty score (based on age, medical history‐derived Charlson Comorbidity Index, and ECOG performance status); frailty scores: 0 = fit, 1 = intermediate (int), and ≥2 = frail. Results: Pt frailty status was balanced between treatment arms in ASPIRE and ENDEAVOR. Median PFS and OS were longer with K‐based regimens vs controls in ASPIRE and ENDEAVOR across frailty subgroups (Table). Rates of treatment‐emergent adverse events are summarized in the Table. Summary/Conclusion: Kd56 and KRd consistently improved outcomes vs Vd and Rd, respectively, in all frailty subgroups as defined by the algorithm above. These findings support the favorable benefit‐risk profile of KRd and Kd56 regardless of frailty score.